In yesterday’s Wall Street session, Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shares traded at $9.42, down -1.15% from the previous session.
16 analysts cover Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $54.00 and a low of $8.00, we find $18.00. Given the previous closing price of $9.53, this indicates a potential upside of 88.88 percent. ICPT stock price is now -39.64% away from the 50-day moving average and -41.41% away from the 200-day moving average. The market capitalization of the company currently stands at $392.72M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
The stock has received a hold rating from 10 analysts and a buy rating from 2. Brokers who have rated the stock have averaged $20.17 as their price target over the next twelve months.
.
Insiders disposed of 33,618 shares of company stock worth roughly $0.32 million over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ICPT stock. A new stake in Intercept Pharmaceuticals Inc. shares was purchased by ADAGE CAPITAL PARTNERS GP, L.L.C. during the first quarter worth $4,130,000. PRUDENTIAL FINANCIAL INC invested $2,123,000 in shares of ICPT during the first quarter. In the first quarter, MARSHALL WACE, LLP acquired a new stake in Intercept Pharmaceuticals Inc. valued at approximately $1,067,000. JANE STREET GROUP, LLC acquired a new stake in ICPT for approximately $820,000. PROFUND ADVISORS LLC purchased a new stake in ICPT valued at around $451,000 in the second quarter. In total, there are 228 active investors with 80.60% ownership of the company’s stock.
On Tuesday morning Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) stock kicked off with the opening price of $9.47. During the past 12 months, Intercept Pharmaceuticals Inc. has had a low of $9.21 and a high of $21.86. As of last week, the company has a debt-to-equity ratio of 4.96, a current ratio of 2.40, and a quick ratio of 2.40. The fifty day moving average price for ICPT is $15.43 and a two-hundred day moving average price translates $16.03 for the stock.
The latest earnings results from Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.77, missing analysts’ expectations of -$0.65 by -0.12. This compares to $0.54 EPS in the same period last year. The net profit margin was 70.30% and return on equity was -812.50% for ICPT. The company reported revenue of $67.96 million for the quarter, compared to $59.15 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.9 percent. For the current quarter, analysts expect ICPT to generate $78.74M in revenue.
Intercept Pharmaceuticals Inc.(ICPT) Company Profile
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.
